Chronic lithium treatment of B-lymphoblast cell lines (BLCLs) from bipolar-I disorder (BD-I) patients and healthy subjects ex vivo attenuates agonist-and thapsigargin-stimulated intracellular calcium (Ca 2 þ ) responses. As these findings suggest that chronic lithium treatment modifies receptor (ROCE) and/or store-operated Ca 2 þ entry (SOCE) mechanisms, we determined whether chronic lithium treatment of BLCLs modified the expression of two members of the transient receptor potential channels (TRPC1 & 3), which participate in ROCE/SOCE. Chronic lithium treatment significantly reduced BLCL TRPC3 immunoreactivity (repeated-measures ANOVA, P ¼ 0.00005), with interaction effects of diagnosis (P ¼ 0.037) and sex (P ¼ 0.040). The lithium-induced decrease was greatest in BLCLs from female BD-I patients compared with those from healthy females (À27%) and with vehicle-treated BLCLs from female BD-I patients (À33%). However, lithium treatment did not affect TRPC1 and 3 mRNA levels, and TRPC1 immunoreactivity. Downregulation of TRPC3 may be an important mechanism by which lithium ameliorates pathophysiological Ca 2 þ disturbances as observed in BD.
INTRODUCTION
Building evidence implicates altered intracellular signal transduction and second messenger function, with attendant alterations in neuroplasticity and cellular resilience, in the pathophysiology of BD. 1, 2 Among the abnormalities noted, disruption of intracellular calcium (Ca 2 þ ) homeostasis is a pivotal transition stage in the progression to cell death, whether by apoptosis or necrosis. 3, 4 Reports of elevated basal and agonist-stimulated intracellular Ca 2 þ concentrations ([Ca 2 þ ] B and [Ca 2 þ ] S , respectively) in mononuclear leukocytes, platelets and transformed B lymphoblast cell lines (BLCLs) from bipolar I disorder I (BD-I) patients [5] [6] [7] therefore suggest that alterations of intracellular Ca 2 þ homeostasis play an important role in the pathophysiological changes that are thought to compromise cellular resilience and adaptive response to cellular stress in BD. The mechanism(s) involved in the altered Ca 2 þ homeostasis are still uncertain, but recent observations implicate possible disturbances in one or more of the molecular modules regulating intracellular Ca 2 þ such as mitochondrial Ca flux, endoplasmic reticulum (ER) Ca 2 þ storage and release, and store-operated and receptor-operated Ca 2 þ entry (SOCE and ROCE). [7] [8] [9] [10] Observations that lithium (Li) treatment impacts Ca 2 þ signaling and homeostatic mechanisms in neuronal and glial cell models, in addition to other nonexcitable cell models, provide yet another line of support for the notion that intracellular Ca 2 þ dynamics are disrupted in BD. For example, chronic Li treatment attenuated NMDA receptormediated Ca 2 þ influx in neuronal preparations. 11 As well, Li treatment decreased both [ 15 Of additional importance, chronic, but not acute, Li treatment of BLCLs at a therapeutic concentration also attenuated G proteincoupled receptor (lysophosphatidic acid, LPA)-mediated and thapsigargin (TG)-induced (SOCE dependent) Ca 2 þ mobilization responses in this surrogate, cellular, pathophysiological model of BD. 9 While the attenuating effects of Li on NMDA-mediated Ca 2 þ influx are mediated through reduced tyrosine phosphorylation of the NR2B subunit of the NMDA gated Ca 2 þ channel, 16 the effect of Li on intracellular Ca 2 þ dynamics in nonexcitable cell models (eg glial cells, platelets, BLCLs) 9, 12, 13, 15 suggests additional mechanisms are likely to be involved in its action. This is particularly important given recent reports of altered glial cell morphometrics and gene expression in postmortem brain of BD patients. 17, 18 Ample evidence supports a role for glial cells, which are nonexcitable cells, in regulating Ca 2 þ homeostasis through glial-neuron interactions, although the mechanisms are not well understood. 19 Unraveling the molecular mechanisms by which Li modifies intracellular Ca 2 þ homeostasis and dynamics in nonexcitable cell models may be equally important to understanding the full spectrum of effects underlying Li's antimanic, mood stabilizing and neuroprotective actions.
Among the molecular mechanisms regulating intracellular Ca 2 þ dynamics that might be disturbed in BD, several recent observations implicate SOCE and ROCE modules. First, TG-induced Ca 2 þ responses, an index of SOCE, were blunted in platelets from BD patients compared with healthy subjects. 8 Recent research directed at elaborating the molecular components and/or mechanisms mediating SOCE and ROCE highlights the key role of several members of the TRP family of cation permeable channels in these processes in nonexcitable cells, such as lymphocytes and platelets. [21] [22] [23] This superfamily of proteins is comprised of three branches distinguished by sequence homology and functional similarities: TRPC (canonical), TRPV (vanilloid) and TRPM (melastatin). 24 Two subgroups within the canonical branch, (TRPC1,4&5 and TRPC3,6&7, respectively) have been implicated in SOCE and ROCE, 24, 25 raising the prospect of the involvement of one or more of these TRPC members in the Ca 2 þ abnormalities that have been reported in BD and the in actions of Li in BLCLs highlighted above.
Accordingly, the specific objectives of this study were, first, to determine whether the expression of selected TRPC candidate subtypes, which have been implicated in SOCE and ROCE, is altered in BLCLs from BD-I patients showing disturbed intracellular Ca 2 þ dynamics and second, to evaluate whether they are altered by treatment of BLCLs with Li. We report here the expression in BLCLs and differential regulation of TRPC3, in contrast to TRPC1, in response to chronic Li treatment of cell lines from BD-I patients ex vivo, at a thereapeutically relevant concentration. The lack of attendant changes in TRPC3 mRNA levels suggests this Li-induced effect is likely mediated through post-translational regulation of TRPC3 levels, changes which in turn may contribute to the attenuating effects of chronic Li treatment on LPA-and TG-evoked intracellular Ca 2 þ responses in BLCLs previously reported. 9 
RESULTS

Subject Demographics
Patient (N ¼ 15) and healthy (N ¼ 10) comparison subjects from whom cell lines were used in this study did not differ in mean age (44. 573.72 years vs 44.474.45, respectively; t ¼ 0.013, P40.05). The proportion of females to males also did not differ significantly between the healthy subject and BD-I groups (Fisher's exact test, P ¼ 1.0). At the time blood samples for B lymphocyte transformation were obtained, the majority of BD patients were euthymic (73%), while 27% were depressed. The most prevalent comorbid psychiatric disorder found in the BD patient group was alcohol abuse/ dependence (20%). Other comorbidities included eating disorder (1), panic disorder (1), and social phobia (1) . There was a positive family history of mood disorders in firstdegree relatives in 47% of the patients, whereas 20% gave a negative history; in the remaining patients the history was uncertain or unknown. In all, 40% of BD patients were receiving Li monotherapy and a similar proportion was on anticonvulsant mood-stabilizer monotherapy at the time of blood sampling.
Characterization of TRPC mRNA Amplification of cDNA reversed transcribed from human brain tissue and BLCL total RNA with TRPC1, TRPC3 and TRPC4 primer sets yielded single PCR products of expected sizes 92 bp for TRPC1 (Figure 1a ), 94 bp for TRPC3 ( Figure  1b ) and 100 bp for TRPC4 (data not shown), respectively. While TRPC6 primer sets yielded a single PCR product of 98 bp in human brain tissues, no detectable product was identified in BLCLs (data not shown). All standard curves from the PCR reactions showed correlation coefficients 40.98 supporting the linear dynamic range (1-10 À4 ) of the assay. The efficiencies of PCR reactions, as estimated by the slopes of the standard curves (10 (1/ÀSlope) -1), 26 were 498%.
Characterization of TRPC Immunolabeling Specificity
Anti-TRPC1 detected a major band of estimated molecular mass of 83 kDa in BLCLs, and the positive control tissues, rat and mouse cerebral cortex (Figure 1c ). With respect to TRPC3, anti-TRPC3 antibody detected one major immunoreactive band with apparent molecular weight of 123 kDa in BLCLs and rat cortex but not platelets (negative control) (Figure 1d (Figure 1f ), respectively). Table 1 ). In contrast, there was a significant main effect of drug-treatment (F ¼ 25. Figure 2 ). Analysis of simple effects revealed that TRPC3 immunolabeling decreased significantly and to a greater extent in chronic-Litreated BLCLs from female BD-I patients as compared with vehicle-treated BLCLs from female BD-I patients (-33 %, P ¼ 0.00002) and BLCLs, treated chronically with Li, from healthy females (À27%, P ¼ 0.00003). Chronic Li treatment also reduced TRPC3 immunoreactivity in BLCLs from female healthy subjects as compared with vehicle-treated cell lines (-16%, P ¼ 0.019). A comparable reduction was also observed in chronic-Li-treated BLCLs from male BD-I patients as compared with vehicle-treated cells from male BD-I patients (-18%, P ¼ 0.028). A decrease of similar magnitude in mean TRPC3 immunolabeling of chronic-Li-treated BLCLs from male BD-I patients relative to that in Li-treated BLCLs from healthy male subjects (À19%, P ¼ 0.052) fell short of achieving statistical significance, however. In contrast, there was no effect of chronic Li treatment compared to vehicle in BLCLs from healthy male subjects. Finally, there were no significant correlations between the mRNA levels of TRPC1 and TRPC3 and the immunoreactive levels of the corresponding proteins, respectively, in BLCLs from any of the comparison groups (data not shown).
Relationship between Ca 2 þ Mobilization Measures and, TRPC1 and TRPC3 Protein Levels in BLCLs from BD-I Patients and Healthy Subjects
Given the role of TRPCs in modulating Ca 2 þ influx, we examined whether there were relationships between previously measured parameters of Ca 2 þ homeostasis determined in these cell lines, 7, 9 and TRPC3 and TRPC1 protein levels in BLCLs from BD-I patients and healthy subjects. TRPC3 protein levels in both vehicle-and Li-treated BLCLs from BD-I and healthy controls did not correlate with either [Ca 2 þ ] B , LPA-stimulated [Ca 2 þ ] S , or any TG-stimulated SOCE-mediated responses (data not shown). Similarly, there were no statistically significant correlations between TRPC3 levels and the respective TG-stimulated SOCE-mediated responses in the same BLCL samples, both normalized to Normalized immunolabeling densities were analyzed by repeatedmeasures ANOVA while group (diagnosis, sex) by Li treatment interaction effects were further evaluated by analysis of simple effects as described in Materials and Methods. *Indicates Po0.05 compared with vehicle-treated cell lines within the same sex and **Indicates Po0.0005 compared with vehicle-treated BLCLs from female BD-I patients and chronic Li-treated BLCLs from BD-I female patients compared with healthy females. wIndicates P ¼ 0.052 compared to vehicle-treated BLCLs from BD-I male subjects. 
DISCUSSION
The principal finding of this study is the demonstration for the first time of a selective effect of chronic treatment at a therapeutically relevant concentration of Li to reduce TPRC3 protein levels in BLCLs from BD-I patients (À29%) as compared with those from healthy subjects (À5%). These observations complement our recent report 9 that chronic Li treatment of BLCLs blunts agonist-and TG-stimulated Ca 2 þ responses, and implicate these protein changes, in part, in this effect. Collectively, these observations illuminate further the spectrum of actions of Li that may be relevant to its mood stabilizing and antimanic effects. Moreover, the greater magnitude of the TRPC3 reductions in chronically Li-treated BLCLs from BD-I patients is particularly germane to the notion that disrupted intracellular Ca 2 þ homeostasis plays an important pathophysiological role in BD and that the correction of these disturbances is a critical component of Li's mood-stabilizing action.
As the veracity of the findings are contingent upon the specificity and quantitative accuracy of the immunoblot and PCR assays used, some comment on these is merited prior to elaborating further on the nature and basis for the TRPC changes observed. Of the TRPC subtypes screened in BLCLs, only TRPC 1, 3 and 4 mRNA could be detected by real-time PCR with the unique primers used and sequences confirmed. Using epitope specific polyclonal antibodies, TRPC 1 and 3 subtype expression was further confirmed in BLCLs. Briefly, the putative TRPC1 protein band comigrated with immunoreactive bands detected with TRPC1-antiserum in rat and mouse cerebral cortex in which TRPC1 is known to be highly expressed. 27 The putative TRPC3 protein band had a similar migratory pattern to that of an immunoreactive protein detected with TRPC3-antiserum in rat cerebral cortex. No immunoreactive TRPC3 band was detected in lysates from platelets, which lacks TRPC3 mRNA (negative control). 28 Tissue-and cell-type-dependent expression of various TRPCs subtypes has been reported, but TRPC1 and TRPC3 subtypes have been identified in some hemopoietic cells, and in rat and human brain. 29, 30 The present findings extend the demonstration of both TRPC1 and TRPC3 expression, based on mRNA and protein levels, to human BLCLs, as well.
Although no differences were found between BD-I patients and healthy comparison subjects in either TRPC3 or TRPC1 protein and mRNA levels in vehicle-treated BLCLs, the perturbation of chronic treatment of BLCLs with Li elicited a differential effect on TRPC3 protein levels in cell lines from BD-I patients as compared with healthy subjects. This was manifest in significant interactions of Li treatment with diagnosis, as well as sex. The analysis of simple effects revealed a statistically significant effect of diagnosis when both treatment and sex were held constant. Tests of contrasts among the entire set of group cell means revealed that the greatest Li-induced reductions in TRPC3 levels occurred in BLCLs from female BD-I patients (À33%); the decrement in BLCLs from male BD-I patients was smaller (À18%). The differential diagnostic effect not with standing, the statistically significant, although smaller magnitude of the reduction in TRPC3 levels in Li-treated BLCLs from healthy female subjects (À16%) compared with vehicle, together with the lack of Li effect in male healthy controls, indicates an enhanced sensitivity of the Li perturbation in females, in general.
The latter findings together with recent evidence of sexdependent abnormalities in variables such as basal and NaFstimulated cAMP production in BLCLs from BD-I patients 31 and in inositol monophosphatase 2 mRNA expression in both BLCLs and postmortem temporal cortex from BD-I patients 20 support the notion that sex-related differences in pathophysiology may occur in BD. That said, a caveat is the potential confounding effect of extraneous factors such as Li responsiveness or illness course and pattern specifiers. In this regard, five of the 10 female BD-I patients were receiving Li monotherapy and presumptive Li responders in contrast to only one out of the five male BD-I patients, and half of the female but none of the male BD-I patients met criteria for seasonality. While these attributes are important variables for exploration in their own right, the small sample size of the subject groups at this stage of study limits more detailed analysis of the potential effect of these factors and to explore their predictive potential.
Unlike the reduction in TRPC3 protein, Li treatment did not affect its mRNA levels. While it is tempting to speculate that the latter observations imply that the mechanism(s) underlying the effect of Li treatment involves factors regulating the disposition and clearance of the TRPC3 protein at the post-translational level, the large variance in the mRNA measures (up to 6-fold) in the comparison groups, which likely reflects intersubject and natural genetic variations in the gene expression, [32] [33] [34] may have obscured changes in mRNA levels. That said, the variance of the mean differences for the within-subject Li treatment effect was considerably smaller (CV ¼ 160%) than that for the between-subject comparisons (range of CVs ¼ 210-585%). Thus, Li-induced changes in mRNA levels should have been more amenable to detection.
Little is known at the present time of the specific mechanisms by which TRPC3 is targeted for degradation in the cell. These uncertainties aside, the reduction in TRPC3 levels together with the observation that Li attenuates TG-induced Ca 2 þ influx (a measure of SOCE), suggest that Li may modify intracellular Ca 2 þ dynamics through SOCE mechanisms, at least in part, by downregulating TRPC3 at the protein level. While the lack of a correlation between the Li-induced decrements in the latter functional measure and TRPC3 immunolabeling relative to vehicle-treatment seems to conflict with this conclusion, it is not clear yet whether global TG-induced Ca 2 þ mobilization changes in direct proportion to the levels of TRPC3. The functional effects of TRPC3 in modulating SOCE have been shown to vary in relation to its expression levels: 23 at low levels TRPC3 operates as an SOCC, whereas at high expression levels it shows G protein receptor-coupled phospholipase C-operated characteristics. 21 The notion that pathophysiologically and diagnostically distinctive Ca 2 þ homeostasis abnormalities occur in BD-I disorder has grown out of series of observations of differential changes in indices of Ca 2 þ dynamics measured in surrogate peripheral blood cell and BLCLs models from BD, comparison mood and nonmood disorder patients, and healthy subjects. Elevated [Ca 2 þ ] B and enhanced stimulated Ca 2 þ responses are consistent findings in peripheral blood cell (platelet, mononuclear leukocyte and BLCL) preparations from BD patients compared with controls. 1 The notion that these changes are trait-dependent, first suggested by findings that the abnormalities persist after remission, 35, 36 was further strengthened by the demonstration of similar elevated [Ca Although only cell lines from BD-I and healthy subjects were compared in the present study, the effect of chronic Li treatment to reduce TRPC3 protein levels differentially in BLCLs from BD-I patients suggests that this effect may be specific to BD-I or a clinical attribute that cosegregates with the diagnostic group. Of additional note, the TRPC3 changes found in this study appear to be a specific effect attributable to Li, as chronic treatment of the same cell lines with a therapeutic concentration of valproate did not lower TRPC3 immunoreactive levels as compared with vehicle in either BD or healthy subjects (Kwan M et al., unpublished data). Finally, the fact that the TRPC3 changes are confined to BLCLs from BD-I patients argues against the possibility that the findings are an epiphenomenon of Li treatment.
In summary, the findings of this study provide the first evidence that the putative SOCC TRPC3 is affected in a disease-specific manner by chronic treatment with a therapeutically relevant concentration of Li. Against the backdrop of building evidence implicating abnormal intracellular Ca 2 þ homeostasis in the pathophysiology of BD and the modulation of intracellular Ca 2 þ dynamics by Li, these disease-specific effects of chronic Li treatment on TRPC3 raise the possibility that they are intimately linked to the pathophysiology of this disorder and represent an important target involved in the mood-stabilizing response. Elaboration of the specific post-translational molecular mechanisms involved in the Li-induced downregulation of TRPC3 protein levels and the functional impact on intracellular Ca 2 þ dynamics will help to illuminate their specific role in the development of BD and in response to Li treatment.
MATERIALS AND METHODS
Subject B-Lymphoblast Cell Lines
BLCLs were selected from both fresh and frozen stocks prepared from samples from BD patients and age-and sexmatched healthy subjects participating in studies of signal transduction disturbances in mood disorders. 6, 9, 20, 37 Patients had a DSM-IV diagnosis of BD-I as established by the Structured Clinical Interview for DSM-IV (SCID), were physically healthy and had no recent (43 months) drug or alcohol abuse. 6 Healthy subjects had no past or current psychiatric illness as determined by SCID-I (nonpatient version) and were physically healthy as determined by systems review and physical examination. All subjects provided informed written consent. This study was approved by Human Subjects Review Board of the University of Toronto.
Establishment of B Lymphoblast Cell Lines
EBV-transformed BLCLs were prepared using standard techniques as previously described. 6 BLCLs were initially expanded in suspension culture in a 95% air/5% CO 2 humidified incubator at 371C for 13-16 passages (2-3 days/passage), then assayed for [Ca 2 þ ] B , 6, 7 and either frozen and stored in the vapor phase of liquid nitrogen for later regeneration and use, or, in some cases, expanded further for study.
BLCL Growth, Regrowth and Drug Treatment Protocol
BLCLs, either freshly grown or regrown from liquid nitrogen storage, were passaged minimally to obtain the required cell count (6-12 Â 10 7 cells). During this phase, B-cell media, consisting of RPMI, 20% FBS, 2 mM L-glutamine, 1 mM pyruvate, 100 mg/ml streptomycin, 100 U/ml penicillin, was completely replaced every 2-3 days. Cells were counted using a hemocytometer and viability determined by trypan blue exclusion at each replacement of medium.
Once cells had reached the required cell count and viability (490%), three equivalent aliquots were transferred to separate Falcon T-75 flasks; one containing B-cell media with 0.75 mM LiCl and the other two containing equivalent volumes of media to which the aqueous vehicle (saline) was added. To maintain a constant Li concentration, media was completely replaced with gentle sedimenting of the cells by centrifugation (50 g, 10 min) followed by resuspension of the cells, every other day for the first 6 days. For the last 24 h of the 7-day treatment period, cells receiving Li chronically were treated with serum-free medium containing LiCl (0.75 mM) in RPMI 1640, whereas cells receiving vehicle treatment were divided into two batches. One batch was resuspended in serum-free medium containing 0.75 mM Li in RPMI 1640 for the final 24 h of incubation (acute Li treatment), whereas the other batch was resuspended in serum-free RPMI-1640 with vehicle.
Isolation of Total Cellular RNA and Synthesis of First-Strand cDNA Total RNA from 1 Â 10 7 BLCLs were isolated using an RNeasy kit (Qiagen, Chatsworth, CA, USA) according to the manufacturer's instructions. First-strand cDNA was synthesized in a 20 ml mixture containing 1 mg of DNase-treated total RNA, 2 ml of random decamer primers (50 mM, Ambion, Austin, TX, USA), 5 Â first-strand buffer (Gibco BRL, Gaitherburg, MD, USA), 1 ml of 0.1 M dithiothreitol (DTT) and 10 mM dNTPs, 20 U RNAsin (40 U/ml, Promega, Madison, WI, USA), and 200 U Superscriptt RNase H -reverse transcriptase (Gibco BRL). The reaction mixture was incubated for 1 h at 421C and the reaction stopped by heating for 15 min at 701C. The resulting cDNA was diluted in 80 ml deionized, reverse osmosis-purified H 2 O, aliquoted and stored at À201C until use. As a control, one reverse transcription reaction was performed in the absence of RNA in all assays. The efficacy of positive reactions and negative controls for DNA contamination was assayed by PCR for a-tubulin in a 25 ml volume containing 1 Â QIAGEN PCR buffer (including 1. Real-time PCR reactions were carried out using the Quantitect SYBR Green PCR kit (Qiagen). Each 25 ml PCR mixture contained 12.5 ml Quantitect SYBR Green PCR Master Mix, (HotStarTaq DNA polymerase, dNTPs, 5 mM MgCl 2 and fluorescent SYBR Green I dye), 200 nM of TRPC 5 0 and 3 0 primer or 200 nM 18S primers (QuantumRNAt competimer kit, Ambion, Austin, TX), respectively, 1 nM fluorescien dye, 1 ml of five-fold diluted first-strand cDNA, and RNase-free H 2 O. PCR conditions consisted of initiation at 951C for 15 min, followed by 55 cycles of 951C for 30 s, 591C for 30 s and 721C for 45 s. PCR reactions for subject samples were performed in duplicate with standard and negative control samples in the same 96-well plate. A standard curve plotting threshold cycle (CT) values against input quantity (log scale) was constructed for each amplicon. 38 The identities of the PCR products were verified based on their sizes and nucleotide sequences (determined by the DNA Sequencing Facility, Center for Applied Genomics, Hospital for Sick Children, Toronto, ON, Canada), which were compared to the GenBank database using the BLAST search on the National Center for Biotechnology Information web site. The relative concentration of the target gene for subject samples was calculated from a standard curve of threshold cycle vs incremental mRNA concentration derived from pooled RT sample. To correct for sample-to-sample variation in transcript abundance, the amplicon 18S rRNA was also amplified with the target genes. Since transcript abundance values derived for 18S did not differ between drug-treated and diagnostic groups, it served as an internal reference against which TRPC values were normalized. Finally, melting-curve analysis was used to ensure the production of a single PCR product.
B-Lymphoblast Preparation and Western Blotting
B-lymphoblasts and comparison control tissues were prepared as described by Rosado and Sage 22 with slight modifications. Briefly, aliquots of BLCLs (2 Â 10 7 cells), and rat and mouse cerebral cortex (100-300 mg; positive control) were thawed on ice and suspended in 200 ml of lysis buffer, pH 7.2, containing 316 mM NaCl, 20 mM Tris, 2 mM EGTA, 0.2% SDS, 2% sodium deoxycholate, 2% Triton X-100, 2 mM 4-(2-aminoethyl) benzenesulfonylfluoride, 100 mg/ml leupeptin, 5 mg/ml aprotinin and 10 mM benzamidine. Samples were then sonicated using a Vibra Cell Sonicator for 10 s with 2-s pulses at 80% intensity, placed on ice for 30 min, and then sonicated once again. Insoluble debris was removed by centrifugation (10 000 g, 10 min, 41C). Supernatants were removed and protein was determined using the Bradford method. 39 Aliquots of increasing membrane protein concentration from each sample (4-12 mg protein for TRPC1 and 2-8 mg protein for TRPC3) were then prepared for SDS-PAGE by the addition of 2 Â Laemmli buffer, heated (3 min, 951C) and resolved on 10% polyacrylamide gels. Anti-TRPC4 and anti-TRPC6 antibodies from Alomone and Santa Cruz Inc., respectively, did not elicit any immunoreactive signals in these preparations and, thus, examination of these TRPC subtypes in BLCLs was not pursued further. The subsequent focus of study was directed to characterization of the specificity of detection and quantification of TRPC1 and TRPC3 in BLCLs from BD patients and healthy subjects. For TRPC3 immunoblotting, samples were electrophoretically transferred to PVDF membranes and blocked with 5% egg white albumin (1 h, 41C). For TRPC1, sample proteins were transferred to nitrocellulose membranes and blocked with 5% bovine serum albumin (1 h, 41C). For immunodetection, anti-TRPC3 (Alomone) was used at a dilution of 1:200 while anti-TRPC1 (Santa Cruz) was used at a dilution of 1:100. Protein A-labeled HRP was employed as a secondary antibody (1:3000) for anti-TRPC3 detection, while anti-goat IgG (1:5000) was employed for anti-TRPC1. Immunoreactive proteins were detected with ECL þ chemiflourescence system (Amersham Biosciences). For quantitative purposes, assay conditions were established within a linear range of protein concentrations. Immunoreactive signals were normalized against pooled sample run in triplicate on each blot to control for blot-to-blot variation. Signal intensities of TRPC immunoreactive bands were quantified using a Storm phosphorimaging system and ImageQuant software (Molecular Dynamics, Sunnyvale, CA, USA).
Statistical Analysis
Normalized transcript abundance and immunolabeling densities were analyzed by repeated-measures ANOVA, with diagnostic grouped sex as between-measures factors and drug treatment as the within-measures factor. Group (diagnosis, sex) by Li treatment interaction effects were further evaluated by analysis of simple effects and tests of contrasts. 40 Correlations between dependent variables were evaluated using the Pearson Product Moment test. Tests of differences in frequencies of sexes among comparison groups was evaluated using the Fisher Exact Test and of differences in mean ages of groups, using Student's unpaired t-test. All data are expressed as the mean7SD. Statistics with Pr0.05 were taken as significant. Statistical analyses were performed using the SPSS software, version 10 (SPSS Inc.).
